

Prestigious Clinical Cancer Research Journal Publishes HER-Vaxx Phase 1B Data

Sydney, Australia, 29 April 2021: Imugene Limited (ASX:IMU) a clinical stage immuno-oncology company is pleased to announce that the Phase 1b clinical trial data for its B cell peptide cancer immunotherapy HER-Vaxx has been published in the prestigious American Association for Cancer Research journal Clinical Cancer Research.

The title of the article is " Clinical and immunologic responses to a B-cell epitope vaccine in HER2/neu overexpressing advanced gastric cancer patients - results from Phase 1b trial IMU.ACS.001" and is authored by Professor Dr. Ursula Wiedermann from the Medical University Vienna and study investigators.

HER-Vaxx was well tolerated and safe. The induced HER2-specific antibodies and cellular responses were dose-dependent and correlated with clinical responses. The highest dose (50 µg) was recommended for further evaluation in a Phase II trial, with chemotherapy + HER-Vaxx or chemotherapy alone, which is currently in its final stages of completion. Progression free survival was prolonged in cohort 3, correlating with the vaccine specific humoral and cellular responses.

Imugene's HER-Vaxx is a B-cell peptide cancer immunotherapy designed to treat tumours that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers. The immunotherapy is constructed from several B cell epitopes derived from the extracellular domain of HER-2/neu. It has been shown in pre-clinical studies and in Phase 1b and 2 studies to stimulate a potent polyclonal antibody response to HER-2/neu, a well-known and validated cancer target.

For further information please contact:

Leslie Chong
Managing Director and Chief Executive Officer
T: +61 458 040 433
E: Leslie.Chong@Imugene.com

Follow us on Twitter [@TeamImugene](https://twitter.com/TeamImugene)
Like us on Facebook [@Imugene](https://www.facebook.com/Imugene)
Connect with us on LinkedIn [@Imugene Limited](https://www.linkedin.com/company/Imugene-Limited)

Appendix

Full online details of the manuscript can be found at;

<https://clincancerres.aacrjournals.org/content/early/2021/04/27/1078-0432.CCR-20-3742>.

OnlineFirst articles are published online before they appear in a regular issue of the journal.

About Imugene (ASX:IMU)

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Our unique platform technologies seek to harness the body's immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Our product pipeline includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets.

Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Imugene is well funded and resourced, to deliver on its commercial and clinical milestones. Together with leading specialists and medical professionals, we believe Imugene's immuno-oncology therapies will become foundation treatments for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.

Release authorised by the Managing Director and Chief Executive Officer